GB9524942D0 - Drug therapy - Google Patents
Drug therapyInfo
- Publication number
- GB9524942D0 GB9524942D0 GBGB9524942.1A GB9524942A GB9524942D0 GB 9524942 D0 GB9524942 D0 GB 9524942D0 GB 9524942 A GB9524942 A GB 9524942A GB 9524942 D0 GB9524942 D0 GB 9524942D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- drug therapy
- therapy
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9524942.1A GB9524942D0 (en) | 1995-12-06 | 1995-12-06 | Drug therapy |
PCT/GB1996/003000 WO1997020580A1 (en) | 1995-12-06 | 1996-12-06 | Drug therapy |
CA002239203A CA2239203A1 (en) | 1995-12-06 | 1996-12-06 | Drug therapy |
JP9521082A JP2000502071A (en) | 1995-12-06 | 1996-12-06 | Drug therapy |
EP96940685A EP0865298A1 (en) | 1995-12-06 | 1996-12-06 | Drug therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9524942.1A GB9524942D0 (en) | 1995-12-06 | 1995-12-06 | Drug therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB9524942D0 true GB9524942D0 (en) | 1996-02-07 |
Family
ID=10784998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB9524942.1A Pending GB9524942D0 (en) | 1995-12-06 | 1995-12-06 | Drug therapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0865298A1 (en) |
JP (1) | JP2000502071A (en) |
CA (1) | CA2239203A1 (en) |
GB (1) | GB9524942D0 (en) |
WO (1) | WO1997020580A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
ATE499115T1 (en) * | 1998-09-18 | 2011-03-15 | Immunomedics Inc | ANTIBODIES REFERRED ENZYME PRODRUG THERAPY WITH GLUCURONIDASE |
IL126732A0 (en) * | 1998-10-23 | 1999-08-17 | Intelligene Ltd | Pro drug |
GB0916749D0 (en) * | 2009-09-23 | 2009-11-04 | Mologic Ltd | Peptide cleaning agents |
GB201308363D0 (en) | 2013-05-09 | 2013-06-19 | Bagshawe Kenneth D | Tumour therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
-
1995
- 1995-12-06 GB GBGB9524942.1A patent/GB9524942D0/en active Pending
-
1996
- 1996-12-06 CA CA002239203A patent/CA2239203A1/en active Pending
- 1996-12-06 WO PCT/GB1996/003000 patent/WO1997020580A1/en not_active Application Discontinuation
- 1996-12-06 JP JP9521082A patent/JP2000502071A/en active Pending
- 1996-12-06 EP EP96940685A patent/EP0865298A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2239203A1 (en) | 1997-06-12 |
WO1997020580A1 (en) | 1997-06-12 |
EP0865298A1 (en) | 1998-09-23 |
JP2000502071A (en) | 2000-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9505491D0 (en) | Therapeutic agents | |
GB9523244D0 (en) | Therapeutic agents | |
GB9513118D0 (en) | Therapeutic agents | |
GB9513117D0 (en) | Therapeutic agents | |
GB9505492D0 (en) | Therapeutic agents | |
GB9507291D0 (en) | Therapeutic agents | |
GB9519563D0 (en) | Therapeutic agents | |
GB9507348D0 (en) | Therapeutic agents | |
GB9500580D0 (en) | Therapeutic agents | |
GB9501865D0 (en) | Therapeutic agents | |
GB9523243D0 (en) | Therapeutic agents | |
GB9513467D0 (en) | Therapeutic agents | |
GB9524942D0 (en) | Drug therapy | |
GB9521781D0 (en) | Therapeutic agents | |
GB9522495D0 (en) | Therapeutic agents | |
GB9523065D0 (en) | Therapeutic agents | |
GB9510223D0 (en) | Therapeutic agent | |
GB9519558D0 (en) | Therapeutic agents | |
GB9520731D0 (en) | Therapeutic agents | |
GB9523064D0 (en) | Therapeutic agents | |
GB9522372D0 (en) | Therapeutic agents | |
GB9503377D0 (en) | Therapeutic agents | |
GB9507224D0 (en) | Therapeutic agents | |
GB9521347D0 (en) | Therapeutic agents | |
PL310059A1 (en) | Therapeutic oinment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
730 | Substitution of applicants allowed (sect. 30/1977) | ||
730 | Substitution of applicants allowed (sect. 30/1977) |